The increasing interest in effective weight management has spurred considerable investigation into novel treatments. Recently , Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor activator , has shown promising results in patient trials, indicating potential for substantial weight decrease. Consequ